Business Context and Reporting Period
This Form 8-K was filed by Genprex, Inc. on May 25, 2023. The report details significant updates regarding the Acclaim-1 clinical trial for REQORSA Immunogene Therapy in combination with AstraZeneca's Tagrisso for late-stage non-small cell lung cancer (NSCLC).
Key Financial Metrics
The filing text does not provide specific values for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on clinical trial progress and does not contain financial statements.
Material Changes and Clinical Updates
- Clinical Data Publication: Positive preliminary data from the Phase 1 portion of the Acclaim-1 trial was published in an abstract for the 2023 ASCO Annual Meeting.
- Safety Profile: REQORSA was generally well tolerated with no dose-limiting toxicities observed in the eight patients evaluated.
- Efficacy Results:
- One patient at the 0.06 mg/kg dose achieved partial remission and remained on treatment for approximately 10.5 months (16 cycles).
- Another patient at the 0.09 mg/kg dose achieved stable disease and remained on treatment for approximately 9 months (14 cycles).
- These progression-free survival (PFS) durations exceeded the median PFS observed with osimertinib alone in prior trials.
- Trial Advancement: The Safety Review Committee (SRC) approved the advancement to the Phase 2 expansion portion of the trial.
- Dose Determination: The recommended Phase 2 dose is set at 0.12 mg/kg, which is twice the highest dose used in the company's prior trial combining REQORSA with Tarceva.
Guidance, Outlook, and Risks
- Timeline: The Phase 2 expansion portion is expected to begin in the third quarter of 2023.
- Enrollment Plan: The Phase 2 expansion aims to enroll approximately 66 patients, split between those with prior Tagrisso-only treatment and those with prior Tagrisso plus chemotherapy.
- Interim Analysis: An interim analysis is planned after treating 19 patients in each cohort.
- Risks and Uncertainties: Management cautions that forward-looking statements regarding clinical timelines, regulatory approvals, and capital needs are subject to significant risks. Actual results may differ materially from projections.
Investor Verification Checklist
- Verify the full text of the abstract presented at the 2023 ASCO Annual Meeting for detailed statistical data.
- Monitor the commencement date of the Phase 2 expansion trial in Q3 2023.
- Review the company's most recent Form 10-K for detailed risk factors regarding capital needs and liquidity.
- Track the interim analysis results following the treatment of the first 19 patients in each Phase 2 cohort.